Sevoflurane attenuates hypoxia/reoxygenation-induced cardiomyocyte injury via the LncRNA FAM201A/miR-488-3p/PTEN axis Authors: Chen Yang, Yuanzhi Li, Qiang Li, Xibao Shi, Jinping Li, Ying Chen, Huiling Qin Published: 2025 ABSTRACT AbstractBackgroundMyocardial ischemia-reperfusion injury (IRI) remains a major clinical challenge, and sevoflurane (Sevo) preconditioning has shown cardioprotective effects. However, the underlying molecular mechanisms are incompletely understood. This study aimed to determine whether Sevo alleviates hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury by regulating the lncRNA FAM201A.MethodsTo investigate the cardioprotective effects of Sevo, an optimized in vitro H/R model with Sevo preconditioning was established using H9c2 cardiomyocytes. FAM201A expression was modulated via overexpression plasmids, and miR-488-3p levels were altered using miRNA mimics in combination with Sevo exposure. Cell apoptosis, membrane integrity (cTnI, CK-MB), inflammatory responses (IL-6, TNF-α), and oxidative stress markers (SOD, MDA) were assessed. Bioinformatics prediction and dual-luciferase reporter assays validated interactions between FAM201A, miR-488-3p, and their target gene PTEN. Western blot analysis evaluated PI3K/AKT pathway activity.ResultsH/R significantly increased FAM201A expression in cardiomyocytes, which was dose-dependently suppressed by Sevo pretreatment. Overexpression of FAM201A abolished the protective effects of Sevo, as evidenced by exacerbated apoptosis rates, aggravated oxidative stress, and heightened inflammatory cytokine levels. Mechanistically, FAM201A directly interacted with and negatively regulated miR-488-3p. miR-488-3p mimics counteracted FAM201A-induced cellular damage and suppressed PTEN expression, a validated target of miR-488-3p. Furthermore, Sevo-mediated PTEN downregulation and subsequent AKT phosphorylation were reversed by FAM201A overexpression but rescued by miR-488-3p restoration.ConclusionsSevo preconditioning protects against H/R injury by downregulating FAM201A, which sponges miR-488-3p to reduce PTEN and activate PI3K/AKT signaling. Targeting this axis may provide potential therapeutic targets for IRI.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12871-025-03545-6.Keywords: Sevoflurane, FAM201A, MiR-488-3p, PTEN, Hypoxia/reoxygenation, Cardiomyocyte injury Background Myocardial ischemia-reperfusion injury (IRI) is a critical challenge in acute myocardial infarction and cardiac surgery. It involves mitochondrial dysfunction, reactive oxygen species (ROS) overproduction, and apoptotic signaling triggered by hypoxia/reoxygenation (H/R). Although revascularization therapies have significantly reduced acute mortality, residual IRI still leads to irreversible myocardial damage and adverse outcomes [1, 2]. In recent years, anesthetic preconditioning has emerged as a promising strategy due to its endogenous protective effects [3]. Among these, sevoflurane (Sevo), an inhalational anesthetic, attenuates cardiomyocyte apoptosis and improves mitochondrial function by inhibiting ROS generation and activating prosurvival signaling pathways such as PI3K/Akt [4, 5]. However, the precise molecular regulatory network underlying Sevo preconditioning remains incompletely understood, limiting its clinical translation and the development of precision intervention strategies. Long non-coding RNAs (lncRNAs), as core components of epigenetic regulatory networks, play pivotal roles in the pathogenesis of cardiovascular diseases. Recent studies have revealed that lncRNAs participate in the regulation of oxidative stress, inflammation, and apoptosis during IRI through mechanisms including microRNA (miRNA) sponging, protein-protein interactions, and chromatin modification. For instance, lncRNA H19 exacerbates IRI by sequestering miR-877-3p to promote pro-inflammatory cytokine release [6], whereas lncRNA promotes apoptotic processes in cardiomyocytes through autophagic regulation [7]. Notably, anesthetic preconditioning effects are closely associated with dynamic lncRNA regulation, such as, mitigates myocardial ischemia-reperfusion injury by downregulating lncRNA NEAT1, which subsequently modulates the miR-140/RhoA signaling axis [8]. Despite these advances, the role of lncRNAs in Sevo preconditioning remains largely unexplored. FAM201A, a newly identified lncRNA, exhibits diverse regulatory functions across various pathological contexts. In neuroblastoma, FAM201A-encoded small protein NBASP inhibits tumor progression via the FABP5/MAPK pathway [9], while in cervical cancer, FAM201A promotes cell survival by activating Wnt/β-catenin signaling through the miR-1271-5p/Flotillin-1 axis [10]. Notably, FAM201A also exacerbates inflammatory damage in chondrocytes via a miR-146a-5p/POU2F1 positive feedback loop [11]. Bioinformatics analyses further suggest its potential association with myocardial injury in atrial fibrillation [12]. Collectively, these findings highlight FAM201A as a critical node in cellular stress responses, yet its role in myocardial IRI remains unknown. Given the functional versatility of FAM201A and its potential involvement in cardiac pathologies, we hypothesize that Sevo-preconditioning attenuates H/R-induced cardiomyocyte injury by suppressing FAM201A expression. To test this hypothesis, we established a Sevo-preconditioned H/R model in cardiomyocytes, systematically analyzed FAM201A expression profiles and their effects on cell apoptosis, inflammation and oxidative stress, and further explored downstream regulatory mechanisms. This study aims to uncover a novel FAM201A-mediated cardioprotective pathway, providing theoretical foundations for optimizing Sevo preconditioning strategies and developing targeted therapies for IRI. Methods Cell culture Cell culture and transfection procedures were performed as previously optimized [13]. The H9c2 cells (rat cardiomyocyte cell line; China Center for Type Culture Collection, CCTCC, Shanghai, China) were maintained in Dulbecco’s Modified Eagle Medium (DMEM; Cat# C11995500BT, Gibco, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Cat# 10099-141, Gibco, Waltham, MA, USA) under controlled atmosphere (5% CO2, 37 °C). Initial culture stabilization required 72-hour stationary incubation followed by medium renewal every third day. At 80% confluence, cell dissociation was achieved through trypsin/EDTA treatment (0.25%, Cat# 25–053-CI, Corning, NY, USA). Establishment of H/R model and Sevo treatment To determine the optimal hypoxia exposure time, H9c2 cells were subjected to hypoxia for 3, 6, or 12 h in a gas-controlled chamber (95% N₂/5% CO₂), followed by 6-hour reoxygenation in standard medium under normoxic conditions (95% air/5% CO₂). Control groups were maintained under standard normoxic conditions (95% air/5% CO₂) throughout the experimental timeline for the equivalent total duration. For Sevo treatment, cells were divided into three groups: (1) normoxic controls, (2) H/R-exposed cells (6-hour hypoxia + 6-hour reoxygenation), and (3) H/R cells treated with Sevo. In the Sevo group, cells were exposed to 1.5%, 2.5%, or 3.5% Sevo (v/v) during the hypoxia-to-reoxygenation transition using a calibrated vaporizer (Vapor 2000, Draeger, Lübeck, Germany). Sevo was delivered in a gas mixture (97.6% air/5% CO₂) for 20 min, with concentrations verified via infrared gas analyzer (Datex-Ohmeda). All treatments were performed in triplicate, and cellular responses were assessed using standardized viability. This protocol aligns with established H/R injury models [14] and volatile anesthetic preconditioning methodologies [15]. Cell transfection H9c2 cells in logarithmic growth phase were seeded into 6-well plates and allowed to reach 80% confluence prior to transfection. Plasmid solutions (50 nM working concentration) were prepared following manufacturer’s protocol (Lipofectamine 3000, Cat# L3000015, Thermo Fisher Scientific, Waltham, MA, USA). The transfection plasmid included: oe-FAM201A (FAM201A overexpression plasmid), oe-NC (negative control plasmid), miR-488-3p mimic and miR-NC. These plasmids were transfected into Sevo -H/R cardiomyocytes. Untransfected control groups included: blank control (no treatment), H/R-treated cells, and Sevo -treated H/R cells. Post-transfection (48 h), successful gene manipulation was confirmed through RT-qPCR analysis of FAM201A and miR-488-3p expression profiles. RT-qPCR Cells from each experimental group were first harvested and lysed with TRIzol reagent (Cat# 15596026, Invitrogen, Waltham, MA, USA) according to the manufacturer’s instructions. Following centrifugation at 12,000 × g for 15 min at 4 °C, the supernatant was collected, and total RNA was purified using chloroform extraction and isopropanol precipitation. RNA quality and integrity were evaluated via 1% agarose gel electrophoresis and NanoDrop spectrophotometry. cDNA was synthesized from 1 µg of total RNA using a reverse transcription kit (PrimeScript RT Reagent Kit, Cat# RR037A, Takara, Tokyo, Japan) under the following conditions: 37 °C for 15 min and 85 °C for 5 s. qPCR was performed with SYBR Green Master Mix (Cat# 04887352001, Roche, Basel, Switzerland) on a LightCycler 480 system. The cycling parameters were: pre-denaturation at 95 °C for 5 min, followed by 40 cycles of 95 °C for 10 s, 60 °C for 30 s, and 72 °C for 15 s. Relative expression levels of FAM201A and miR-488-3p were normalized to endogenous controls GAPDH (for mRNA) and U6 snRNA (for miRNA) using the 2−ΔΔCt method. The primer sequences used for RT-qPCR are listed in Table S1. Dual-luciferase reporter assay Bioinformatics prediction of the binding sites between miR-488-3p and FAM201A as well as PTEN was performed using the lncRNASNP2 database (https://guolab.wchscu.cn/lncRNASNP/#!/) and TargetScanHuman (https://www.targetscan.org/vert_72/). The wild - type (WT, containing the binding site) and mutant (MT, lacking the binding site) 3’UTR fragments of the target genes were synthesized by GenScript and then cloned into the psiCHECK2 vector (Cat# C8021, Promega, Madison, WI, USA). H9c2 cells were co-transfected with the recombinant plasmid and miR-488-3p mimic, inhibitor, or NC using Lipofectamine 3000 Transfection Reagent. Following a 48-hour incubation period, the Dual-Glo® Luciferase Assay System (Cat# E2920, Promega, Madison, WI, USA) was used to measure both firefly and Renilla luciferase activities. Subsequently, Renilla signals were normalized to firefly values. RNA immunoprecipitation (RIP) assay The Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore, Cat# 17–700) was employed to validate the endogenous interaction between FAM201A and miR-488-3p according to the manufacturer’s protocol. Briefly, H9c2 cells subjected to H/R or Sevo + H/R treatment were lysed in complete RIP lysis buffer. Subsequently, 100 µL of magnetic beads conjugated with 5 µg of anti-Ago2 antibody (Abcam, Cat# ab186733) or normal mouse IgG (Millipore, Cat# 03–180, as a negative control) were incubated with the cell lysate containing 2 mg of total protein for 4 h at 4 °C. Following extensive washing, the immunoprecipitated RNA complexes were isolated and purified. Finally, the co-precipitated RNA was reverse-transcribed and analyzed by qPCR. The enrichment levels of FAM201A, PTEN mRNA, and miR-488-3p in the immunoprecipitates were quantified by RT-qPCR, with Input RNA as the internal reference. Relative enrichment was calculated using the 2^-ΔΔCt method, normalized to the IgG group. Cell viability assessment via CCK-8 assay Cells were seeded in 96-well plates at a density of 2 × 10³ cells per well and cultured under standard conditions. After a 48-hour incubation period, 10 µL of CCK-8 reagent (Cat# CK04, Dojindo Laboratories, Kumamoto, Japan) was added to each well. Plates were subsequently incubated at 37 °C for 4 h. Absorbance was measured at 450 nm using a microplate reader (BioTek Instruments). Cell viability was normalized to untreated control groups (designated as 100% viability). Apoptosis assay Cellular apoptosis was quantified using dual-staining methodology. Following PBS washing (×3), cells were resuspended in 100 µL calcium-enriched binding buffer (BD Biosciences). Subsequent addition of 5 µL FITC-conjugated Annexin V (Cat# 640945, BioLegend, San Diego, CA, USA) and 2 µL propidium iodide (PI) (5 µg/mL, Cat# 556463, BD Biosciences, San Jose, CA, USA)) preceded 20-minute dark incubation at 4 °C. Stained cells were diluted with 400 µL cold buffer and analyzed within 1 h using FACSCanto II (BD) with FlowJo software. Western blot analysis of apoptosis and signaling proteins Protein extracts were prepared from treated cells using RIPA buffer supplemented with protease and phosphatase inhibitors. Lysates were separated via SDS-PAGE and transferred to PVDF membranes. After blocking with 5% non-fat milk for 1 h, membranes were incubated overnight at 4 °C with primary antibodies against Bcl-2 (Cat# 2870 S, 1:1,000), Bax (Cat# 5023 S, 1:1,000), Cleaved-caspase-3 (Cat# 9664 S, 1:800), PTEN (Cat #9559, 1:1,000), p-AKT (Ser473, Cat# 4060, 1:2,000), Total AKT (Cat# 4691, 1:1,000), p-PDK1 (Ser241, Cat# 3061, 1:1000), p-FOXO1 (Thr24, Cat# 9464, 1:1000), and p-GSK-3β (Ser9, Cat# 5558, 1:1000). β-Actin (Cat# 4970, 1:5,000) served as a loading control. Following HRP-conjugated secondary antibody incubation (Cat# 7074, 1:5,000, 1 h at room temperature), protein bands were visualized using ECL substrate and quantified via ImageJ software. These antibodies were all purchased from Cell Signaling Technology (CST, MA, USA). Normalized data (target protein/β-actin ratio) were derived from three independent experiments to ensure reproducibility. SOD activity assay using WST-1 method Superoxide dismutase (SOD) activity was evaluated using a water-soluble tetrazolium salt (WST-1)-based kit (Cat# S0101, Beyotime Biotechnology, Shanghai, China) in adherence to the manufacturer’s guidelines. Cardiomyocytes were harvested and lysed in ice-cold RIPA buffer supplemented with protease inhibitors. Lysates were centrifuged at 12,000 × g for 15 min at 4 °C, and supernatants were collected. Protein concentration was determined via BCA assay. For SOD quantification, 20 µL of supernatant was combined with 200 µL of reaction solution containing xanthine and xanthine oxidase. The mixture was incubated at 37 °C for 20 min, and absorbance was measured at 450 nm using a microplate reader. SOD activity was calculated based on the inhibition of WST-1 reduction by superoxide radicals, expressed. All samples were normalized to the control group, with results presented as relative SOD activity (mean ± SD) compared to the control. ELISA-based detection of biomarkers Cardiac troponin I (cTnI, Cat# EHcTnI), interleukin-6 (IL-6, Cat# BMS625), tumor necrosis factor-α (TNF-α, Cat# BMS607-3), malondialdehyde (MDA, Cat# BMS607-3), and creatine kinase-MB (CK-MB, Cat# EHCKB,) were quantified using commercial ELISA kits (Thermo Fisher Scientific, Waltham, MA, USA) according to the respective manufacturer’s protocols. Briefly, cell supernatants were centrifuged at 12,000 × g for 15 min at 4 °C to remove debris. Standards and samples were loaded into pre-coated 96-well plates, followed by incubation with biotinylated antibodies and HRP-conjugated streptavidin. After washing, TMB substrate was added, and reactions were stopped with sulfuric acid. Absorbance was measured at 450 nm, and concentrations were calculated using four-parameter logistic regression standard curves. All data were normalized to controls and presented as mean ± SD. Assays for antioxidant enzymes and reactive oxygen species (ROS) Antioxidant enzyme activities and intracellular reactive oxygen species (ROS) were evaluated using established spectrophotometric methods. Glutathione peroxidase (GSH-Px) activity was measured with a commercial kit (Nanjing Jiancheng Bioengineering Institute, Cat# A005) by tracking NADPH oxidation at 340 nm. Catalase (CAT) activity was determined using the ammonium molybdate method (Nanjing Jiancheng, Cat# A007-1-1) based on the decomposition of H₂O₂ at 405 nm. Intracellular reactive oxygen species (ROS) were detected using DCFH-DA (D6883, Sigma-Aldrich, USA): cells loaded with 10 µM DCFH-DA (37 °C, 30 min, dark) were treated, lysed, and 450 nm absorbance measured. All values were normalized to total protein concentration, quantified via BCA kit (23225, Thermo Fisher Scientific). Statistical analysis For multi-group comparisons, one-way ANOVA was used, followed by Tukey’s post hoc test. For pairwise comparisons between two groups, Student’s t-test was applied. Data are presented as mean ± SD from at least three independent biological replicates (each with triplicate technical repeats) and analyzed using GraphPad Prism (v9.5.0, GraphPad Software, San Diego, CA, USA), with p < 0.05 considered statistically significant. Results Optimization of hypoxia duration and sevoflurane concentration for model establishment To establish a reliable H/R model, preliminary screening of hypoxia durations (3, 6, and 12 h) revealed that FAM201A expression was significantly elevated in all groups compared to controls. However, FAM201A levels decreased at 12 h compared to 6 h (Fig. S1A). Cell viability assays demonstrated minimal toxicity at 3 h but severe cytotoxicity at 12 h (Figure S1B), prompting selection of 6-hour hypoxia for subsequent experiments. Further evaluation of Sevo concentrations (1.4–3.4%) showed dose-dependent suppression of H/R-induced FAM201A expression (Fig. S1C). While Sevo exerted cardioprotective effects across this range, 3.4% exhibited reduced efficacy, whereas 2.4% optimally preserved cell viability (Fig. S1D). We further validated the optimization of the model by investigating cell apoptosis/necrosis via flow cytometry. As shown in Supplementary Material 1, the cell necrosis rate remained at a very low level (below 2.5% in all groups), indicating that cell death in the model was dominated by apoptosis rather than necrosis, which is consistent with the characteristics of H/R-induced cardiomyocyte injury (mainly apoptotic death). Notably, the apoptosis rate showed significant changes across groups: 6 h of hypoxia induced a marked increase in apoptosis while maintaining a low necrosis rate, whereas 12 h of hypoxia led to a sharp surge in apoptosis (Fig. S1E). Similarly, compared with other concentrations, 2.4% Sevo exhibited the optimal anti-apoptotic effect (Fig. S1E). These results confirm that our selection of 6 h of hypoxia and 2.4% Sevo is based on a comprehensive assessment of cell death patterns, further supporting the standardization and reliability of the H/R model. FAM201A overexpression reverses sevoflurane-mediated cardioprotection Transfection of oe-FAM201A in the optimized H/R model (6 h hypoxia + 2.4% Sevo) effectively restored FAM201A expression suppressed by Sevo (Fig. 1A). Overexpression of FAM201A exacerbated H/R-induced cardiomyocyte apoptosis, as demonstrated by elevated apoptosis rates (Fig. 1B, specific flow cytometry plots are shown in Supplementary Material 1) and dysregulated apoptosis-related proteins, including reduced Bcl-2/Bax ratios and increased cleaved caspase-3 levels (Fig. 1C, Representative Western blot images for these apoptosis-related proteins are shown in Fig. 1D.). Furthermore, FAM201A overexpression negated the ability of Sevo to attenuate H/R-induced membrane injury markers (cTnI, CK-MB; Fig. 1E), inflammatory cytokines (IL-6, TNF-α; Fig. 1F), and oxidative stress indices (SOD activity, MDA content; Fig. 1G), confirming its antagonistic role in protective effects of Sevo. To further confirm the regulatory role of FAM201A in oxidative stress, we supplemented detection of ROS levels and activities of other antioxidant enzymes (GSH-Px, CAT). As shown in Fig. 1H-J, Sevo reduced H/R-induced ROS accumulation (Fig. 1H) and elevated GSH-Px (Fig. 1I) and CAT (Fig. 1J) activities; however, these protective effects were abolished by FAM201A overexpression. FAM201A Overexpression Abrogates Sevoflurane (Sevo)-Mediated Protection Against Hypoxia/Reoxygenation (H/R) Injury A FAM201A overexpression plasmid (oe-FAM201A) reverses Sevo-mediated suppression of FAM201A in H/R-injured cardiomyocytes B FAM201A overexpression exacerbated H/R-induced cardiomyocyte apoptosis rate suppressed by Sevo C FAM201A overexpression reduced B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax) ratios and increased cleaved caspase-3 levels D Representative Western blot images for Bcl-2, Bax, and cleaved caspase-3 corresponding to the quantitative data in panel C E FAM201A restores H/R-induced membrane injury markers (elevated cardiac troponin I (cTnI), creatine kinase-MB (CK-MB)) F FAM201A reinstates inflammatory cytokine (elevated interleukin-6 (IL-6), interleukin-6 (TNF-α)) secretion suppressed by Sevo G FAM201A negates Sevo’s mitigation of oxidative stress (suppressed suppressed superoxide dismutase (SOD) activity and increased suppressed superoxide dismutase (MDA) levels) H FAM201A overexpression reverses Sevo-induced reduction of intracellular reactive oxygen species (ROS) levels (detected by DCFH-DA assay, absorbance at 450 nm) I FAM201A overexpression abolishes Sevo-mediated elevation of glutathione peroxidase (GSH-Px) activity J FAM201A overexpression counteracts Sevo-induced increase of catalase (CAT) activity. Data are presented as mean ± SD (n = 3 independent experiments). P values for comparisons (vs. control (Ctrl), vs. H/R, vs. H/R + Sevo) are indicated in the figure (one-way ANOVA with Tukey’s post hoc test) FAM201A interacts with miR-488-3p to modulate sevoflurane-mediated cardioprotection Bioinformatics prediction (StarBase) identified the conserved binding sites between FAM201A and miR-488-3p. To verify this interaction, dual-luciferase reporter plasmids containing wild-type (WT-FAM201A) or mutant (MT-FAM201A) FAM201A sequences were constructed (Fig. 2A). Co-transfection of WT-FAM201A with miR-488-3p mimics significantly reduced luciferase activity compared to the control, while MT-FAM201A abolished this effect (Fig. 2B), confirming the specificity of the binding site. To further validate this interaction under endogenous conditions, we performed an RIP assay with an antibody against Ago2, the core component of the RNA-induced silencing complex (RISC). As shown in Fig. 2C, both FAM201A and miR-488-3p were significantly enriched in the Anti-Ago2 immunoprecipitates compared to the negative control IgG, demonstrating that FAM201A and miR-488-3p endogenously co-localize in RISC complexes. H/R suppressed miR-488-3p expression, which was rescued by Sevo but partially reversed by oe-FAM201A (Fig. 2D). Transfection with miR-488-3p mimics restored miR-488-3p levels under Sevo + H/R conditions (Fig. 2D). Importantly, miR-488-3p overexpression counteracted the pro-apoptotic effects of oe-FAM201A, significantly lowering apoptosis rates (Fig. 3A, flow cytometry plots are detailed in Supplementary Material 1.) and restoring apoptosis-related protein balance (Fig. 3B, as shown by Western blots in Fig. 3C). Additionally, miR-488-3p overexpression alleviated membrane injury (Fig. 3D), inflammation (Fig. 3E), and oxidative stress (Fig. 3F), confirming its role as a downstream mediator of FAM201A in H/R injury. Notably, miR-488-3p mimics also rescued the antioxidant defense system, significantly reducing ROS accumulation (Fig. 3G) and restoring GSH-Px (Fig. 3H) and CAT (Fig. 3I) activities that were compromised by FAM201A overexpression. FAM201A Directly Binds and Regulates miR-488-3p A Schematic diagram of the predicted wild-type (WT) and mutant (MT) binding sequences between FAM201A and miR-488-3p B Dual-luciferase reporter assay validating the direct interaction. Co-transfection with miR-488-3p mimic significantly reduced the luciferase activity of the FAM201A-WT reporter but not the FAM201A-MT reporter C RNA immunoprecipitation (RIP) assay showing fold enrichment of FAM201A and miR-488-3p in Argonaute 2 (Ago2) immunoprecipitates relative to immunoglobulin G (IgG) control D Sevo rescues H/R-induced miR-488-3p suppression, reversed by FAM201A overexpression. Data are presented as mean ± SD (n = 3 independent experiments). P values for comparisons (vs. Ctrl (B); vs. anti-IgG (C); vs. Ctrl, vs. H/R, vs. H/R + Sevo, vs. H/R + Sevo + oe-FAM201A (D)) are indicated in the figure (one-way ANOVA with Tukey’s post hoc test) miR-488-3p Mimics Attenuate FAM201A-Driven Injury A miR-488-3p overexpression attenuates FAM201A-induced elevation of apoptosis rates B miR-488-3p restores apoptosis-related protein balance C Representative Western blot images for Bcl-2, Bax, and cleaved caspase-3 D miR-488-3p alleviates FAM201A-aggravated membrane injury E miR-488-3p suppresses FAM201A-induced inflammatory cytokine release F miR-488-3p mitigates FAM201A-exacerbated oxidative stress G miR-488-3p overexpression reduces FAM201A-induced elevation of intracellular ROS levels (DCFH-DA assay) H miR-488-3p restores FAM201A-suppressed GSH-Px activity I miR-488-3p reverses FAM201A-induced reduction of catalase (CAT) activity. Data are presented as mean ± SD (n = 3 independent experiments). P values for comparisons (vs. H/R + Sevo, vs. H/R + Sevo + oe-FAM201A) are indicated in the figure (one-way ANOVA with Tukey’s post hoc test) miR-488-3p targets PTEN to regulate the PI3K/AKT signaling pathway in H/R injury TargetScan prediction revealed a complementary binding site between miR-488-3p and the 3’UTR of PTEN mRNA (Fig. 4A). Dual-luciferase reporter assay showed that co-transfection of WT-PTEN with miR-488-3p mimics reduced luciferase activity compared to control, while MT-PTEN eliminated this suppression (Fig. 4B), confirming PTEN as a direct target of miR-488-3p. RIP assay further verified their endogenous interaction: PTEN mRNA was enriched in Ago2 immunoprecipitates relative to IgG control (p < 0.001), and miR-488-3p showed consistent enrichment in the same complexes (Fig. 4C). These results confirm that miR-488-3p directly binds to PTEN mRNA in vivo. Sevo treatment suppressed H/R-induced PTEN upregulation, an effect reversed by FAM201A overexpression (Fig. 5 A). Modulation of PTEN expression correlated inversely with PI3K/AKT pathway activity: PTEN elevation suppressed p-AKT Ser473 levels, while miR-488-3p-mediated PTEN downregulation restored AKT phosphorylation (Fig. 5B). Notably, total AKT protein levels remained unchanged across all experimental groups (Fig. 5C) (Representative Western blot images for these proteins are presented in Fig. 5D), confirming that these effects were driven by post-translational phosphorylation rather than altered AKT expression. These findings establish PTEN as the critical downstream effector linking miR-488-3p to PI3K/AKT signaling. miR-488-3p Directly Binds to the Phosphatase and Tensin Homolog (PTEN) 3’UTR and Acts as a Regulatory miRNA A Predicted binding site between miR-488-3p and PTEN 3’UTR, with WT retaining the site and MT lacking the core sequence B Dual-luciferase assay shows miR-488-3p mimics reduce activity of WT-PTEN but not MT-PTEN reporter C RIP assay reveals PTEN mRNA and miR-488-3p are enriched in Ago2 precipitates vs. IgG. Data are presented as mean ± SD (n = 3 independent experiments). P values for comparisons (vs. Ctrl (B); vs. anti-IgG (C)) are indicated in the figure (one-way ANOVA with Tukey’s post hoc test) miR-488-3p Targets PTEN to Activate Phosphatidylinositol 3-Kinase/Protein Kinase(PI3K/AKT) Signaling. A FAM201A counteracts Sevo's suppression of PTEN, reversed by miR-488-3p. B PTEN overexpression inhibited AKT Ser473 phosphorylation, while miR-488-3prestored p-AKT levels. C Total AKT protein remained unchanged across all groups. D Representative Western blot images for PTEN, p-AKT (Ser473), and total AKT. Data arepresented as mean ± SD (n=3 independent experiments). P values for comparisons (vs Ctrl, vsH/R, vs H/R + Sevo, vs H/R + Sevo + oe-FAM201A) are indicated in the figure (one-way ANOVA with Tukey's post hoc test) PTEN overexpression reverses miR-488-3p-mediated activation of the PI3K/AKT pathway To definitively establish PTEN’s causal role and comprehensively map the signaling cascade, we performed a rescue experiment by overexpressing PTEN in the context of Sevo preconditioning and miR-488-3p mimic transfection. As summarized in Figure S2, the miR-488-3p mimic significantly suppressed PTEN expression (Fig. S2A), which led to the activation of upstream regulator PDK1 (phosphorylation at Ser241, Fig. S2B) and the core kinase AKT (phosphorylation at Ser473, Fig. S2C). Consequently, the phosphorylation levels of key AKT downstream effectors, including the pro-apoptotic transcription factor FOXO1 (at Thr24, Fig. S2D) and glycogen synthase kinase GSK-3β (at Ser9, Fig. S2E), were markedly elevated. Crucially, this entire activation cascade was significantly reversed by PTEN overexpression. Re-introduction of PTEN restored its protein level and effectively attenuated the enhanced phosphorylation of PDK1, AKT, FOXO1, and GSK-3β (Fig. S2A-E). Discussion Sevo, a widely used inhalation anesthetic in cardiac surgery, has been clinically associated with reduced postoperative myocardial enzyme elevation and lower arrhythmia incidence [16, 17]. Despite its therapeutic benefits, the molecular mechanisms underlying its cardioprotective effects remain incompletely defined due to the intricate network of potential targets. In this study, we identify that Sevo attenuates H/R-induced cellular damage by suppressing lncRNA FAM201A expression. Mechanistically, this suppression prevents FAM201A from sequestering miR-488-3p, thereby activating the PTEN/PI3K/AKT signaling pathway. These results provide mechanistic insights into Sevo’s cardioprotective effects and highlight FAM201A as a potential therapeutic target to mitigate patient-specific variations in clinical outcomes. H/R injury induces multifaceted cellular damage, primarily mediated through apoptotic pathways, sarcolemmal destabilization, inflammatory activation, and oxidative stress dysregulation [18]. Experimental quantification revealed that impaired Bcl-2/Bax equilibrium coupled with caspase-3 activation directly correlates with cardiomyocyte apoptosis, while cTnI and CK-MB levels confirm membrane integrity loss [19]. Concurrently, IL-6 and TNF-α surges demonstrate inflammatory exacerbation, with SOD depletion and MDA accumulation reflecting compromised antioxidant defenses [20, 21]. Therefore, systematic evaluation of these biomarkers demonstrated that 2.4% Sevo exposure significantly mitigated H/R-induced pathological manifestations in cultured cardiomyocytes. These in vitro findings establish preliminary evidence for Sevo’s cytoprotective efficacy at this optimized concentration. Recent studies identify lncRNAs as critical mediators of Sevo-induced cardioprotection. Sevo preconditioning alleviates H/R injury by upregulating lncRNA UCA1 to inhibit autophagy-related APAF1 [22]. Similarly, lncRNA NORAD contributes to Sevo’s protective effects through distinct mechanisms [23]. Consistent with these findings, our study reveals FAM201A as a critical regulatory component in this cardioprotective paradigm. Sevo preconditioning significantly suppressed H/R-triggered FAM201A elevation in cardiomyocytess. Crucially, experimental overexpression of FAM201A neutralized Sevo’s therapeutic efficacy against H/R injury, suggesting its potential involvement in mediating the anesthetic’s protective mechanism. Notably, FAM201A exerts pro-injurious effects in osteoarthritis models by sequestering miR-146a-5p to activate NF-κB signaling [11]. These findings reinforce its role as an evolutionarily conserved mediator of cellular damage while suggesting a molecular sponge mechanism—where competitive miRNA binding modulates pathological processes. This mechanistic paradigm implies FAM201A may similarly regulate myocardial injury through selective miRNA interactions. Accumulating evidence highlights the cytoprotective roles of miR-488-3p in multiple pathological contexts. In cardiomyocytes, it mitigates doxorubicin-induced cardiotoxicity by targeting CyclinG1 [24] and protects against ischemic neuronal death via VPS4B regulation [25]. LncRNAs dynamically regulate miR-488-3p expression: PVT1 inhibits miR-488-3p to promote neuronal apoptosis in epilepsy [26], whereas MIAT knockdown alleviates myocardial hypoxia injury through miR-488-3p/Wnt/β-catenin signaling [27]. Building on this framework, our study identifies FAM201A as a novel upstream regulator of miR-488-3p in cardiomyocytes. Functional rescue experiments demonstrate that miR-488-3p mimics partially reverse FAM201A-overexpression-induced cell damage, supporting the hypothesis that FAM201A-mediated sequestration of miR-488-3p underlies Sevo-induced cardioprotection. The PI3K/AKT pathway is central to myocardial survival, suppressing apoptosis and enhancing oxidative stress resistance [28, 29]. We confirmed that Sevo downregulates PTEN via the FAM201A/miR-488-3p axis, relieving PTEN-mediated inhibition of PI3K/AKT signaling. This aligns with established models where PTEN deletion activates PI3K/AKT to improve mitochondrial function and reduce ROS production. Liang et al. [30] further validated this paradigm, showing miR-30a-5p-mediated PTEN suppression activates PI3K/AKT to inhibit H/R-induced apoptosis. Stable total AKT levels across experimental groups suggest pathway activation depends on post-translational phosphorylation rather than de novo synthesis, reinforcing the role of FAM201A/miR-488-3p/PTEN as an upstream regulatory axis. While this study delineates the FAM201A/miR-488-3p/PTEN pathway’s role in Sevo preconditioning, limitations warrant consideration. First, the exclusive reliance on H9c2 cardiomyocytes, while providing a standardized platform for initial mechanistic screening, necessitates caution in extrapolating these findings to adult human cardiac physiology. The embryonic origin and inherent metabolic characteristics of this cell line differ from mature cardiomyocytes, underscoring the importance of future validation in human induced pluripotent stem cell-derived cardiomyocytes or primary adult cardiomyocytes to confirm the pathophysiological relevance of the identified axis. At the molecular level, the observed decline in FAM201A following prolonged hypoxia may reflect not only cellular disintegration but also potential activation of transcriptional repressors or feedback regulatory mechanisms that merit dedicated investigation. Although direct quantification of PIP3—the canonical lipid product targeted by PTEN phosphatase activity—posed substantial technical hurdles, the consistent phosphorylation patterns observed across multiple downstream nodes (PDK1, AKT, FOXO1, GSK-3β) provide a compelling functional readout of pathway activity. The rescue achieved through PTEN overexpression further solidifies its central regulatory role in this protective cascade. Still, direct PIP3 quantification would strengthen the mechanistic chain, and this limitation should be addressed in future studies. Beyond its established function as a molecular sponge for miR-488-3p, FAM201A may participate in additional regulatory dimensions. Potential nuclear functions, including recruitment of chromatin-modifying complexes or influences on DNA methylation patterns at genomic loci relevant to ischemic injury, represent a compelling avenue for future research. Furthermore, the possibility of synergistic interactions with other cardioprotective lncRNAs, such as FGD5-AS1 [31] and SNHG16 [32], uncover within a broader regulatory network remains to be explored. From a translational perspective, advancing this strategy toward clinical application requires overcoming two major hurdles: optimizing the stability of RNA-based therapeutics through nucleotide chemical modifications (e.g., 2’-O-methylation), and developing efficient cardiac-targeted delivery systems using engineered exosomes or ligand-functionalized nanoparticles. Systematic investigation of sevoflurane’s temporal and concentration-dependent effects, alongside in vivo validation using cardiac-specific FAM201A knockout models, will be crucial steps in translating these mechanistic insights into potential therapeutic interventions. Conclusions In summary, Sevo preconditioning attenuates H/R injury by inhibiting FAM201A, which relieves miR-488-3p suppression, downregulates PTEN, and activates PI3K/AKT signaling. These findings deepen understanding of anesthetic-mediated epigenetic regulation and advance non-coding RNA-based strategies for myocardial protection. Future studies should address translational challenges while exploring broader therapeutic implications. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Acknowledgements No. Abbreviations Long non-coding RNAs Ischemia-reperfusion injury Sevoflurane Hypoxia/reoxygenation Reactive oxygen species microRNA Fetal bovine serum Propidium iodide Superoxide dismutase Creatine kinase-MB Authors’ contributions Study concept and design: Qiang Li and Jinping Li; analysis and interpretation of data: Chen Yang, Yuanzhi Li, Huiling Qin, Qiang Li, Xibao Shi and Ying Chen; drafting of the manuscript: Qiang Li; critical revision of the manuscript for important intellectual content: Chen Yang, Yuanzhi Li and Huiling Qin; statistical analysis: Ying Chen, Chen Yang and Yuanzhi Li. Funding No funds, grants, or other support was received. Data availability All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Chen Yang and Yuanzhi Li are joint first author. Contributor Information Jinping Li, Email: lijinp_shanghai@163.com. Huiling Qin, Email: qinhuiling533000@163.com. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Supplementary Material 4. Data Availability Statement All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.